Khalaph Moneeb, Trajkovska Nadica, Sohns Christian, Guckel Denise, Didenko Maxim, Braun Martin, Imnadze Guram, Lucas Philipp, Fink Thomas, Sciacca Vanessa, Beyer Sebastian, Nageler Gregor, Fleischhauer Jan, Schramm René, Costard-Jäckle Angelika, Fox Henrik, Gummert Jan, Sommer Philipp, El Hamriti Mustapha
Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Heart Rhythm. 2025 Jun 3. doi: 10.1016/j.hrthm.2025.05.060.
Atrial tachycardia (AT) is commonly observed after orthotopic biatrial heart transplantation (O-BA-HTx). Its clinical presentation, relationship to atrial anastomoses, and electrophysiologic characteristics remain controversial. Novel radiofrequency-guided catheter ablation (RFCA) strategies using electroanatomical mapping and myocardial substrate characterization have emerged, but data on their efficacy in this patient group are scarce.
This study aimed to evaluate the efficacy and safety of a novel RFCA strategy for AT in O-BA-HTx patients and assess long-term arrhythmia-free survival.
Overall, 37 consecutive O-BA-HTx patients with therapy-refractory AT underwent prospectively an RFCA between 2017 and 2024. Procedural parameters, acute and long-term outcomes, and complications were assessed.
The cohort (mean age 56.9 ± 16.3 years, 83.8% male) underwent RFCA of AT. Electrophysiologic diagnoses included: The L-line approach, which combines cavotricuspid isthmus and RA-lateral line ablation, was responsible for AT termination in 92.1% (n = 34) of cases. All procedures were performed without any major complications. The median follow-up was 26 months (interquartile range 19-60), and only 2 patients (5.3%) experienced AT recurrence. Remarkably, achieving freedom from AT was associated with freedom from atrial fibrillation, highlighting the effectiveness of addressing AT as a trigger for atrial fibrillation.
The novel L-Line approach is a safe, effective, and reproducible approach for AT ablation in O-BA-HTx patients, with favorable long-term arrhythmia-free survival.
原位双房心脏移植(O-BA-HTx)后常见房性心动过速(AT)。其临床表现、与心房吻合口的关系以及电生理特征仍存在争议。使用电解剖标测和心肌基质特征的新型射频导管消融(RFCA)策略已经出现,但关于其在该患者群体中疗效的数据很少。
本研究旨在评估一种新型RFCA策略治疗O-BA-HTx患者AT的疗效和安全性,并评估长期无心律失常生存率。
总体而言,2017年至2024年间,37例连续的O-BA-HTx且对治疗难治的AT患者前瞻性地接受了RFCA。评估手术参数、急性和长期结果以及并发症。
该队列(平均年龄56.9±16.3岁,83.8%为男性)接受了AT的RFCA。电生理诊断包括:结合腔静脉峡部和右心房外侧线消融的L线方法导致92.1%(n = 34)的病例AT终止。所有手术均未发生任何重大并发症。中位随访时间为26个月(四分位间距19 - 60),只有2例患者(5.3%)经历了AT复发。值得注意的是,实现无AT与无房颤相关,突出了将AT作为房颤触发因素进行处理的有效性。
新型L线方法是一种安全、有效且可重复的O-BA-HTx患者AT消融方法,具有良好的长期无心律失常生存率。